Watch the video and download the slides<\/p>\n
<\/p>\n
The GUIDE Communication Framework: Strengthening shared decision-making between nmCRPC patients and the healthcare team<\/span><\/strong><\/p>\n This is the first in a series of three newsletters<\/strong> explaining the GUIDE Communication Framework<\/strong>, a simple 5-step approach to optimise the role of the nurse in strengthening shared decision-making between nmCRPC patients and their healthcare team.<\/p>\n GUIDE\u2019s five letters each represent a crucial step in your conversations with patients with prostate cancer.<\/p>\n G<\/span><\/strong>ain insight into goals of treatment and care<\/p>\n U<\/span><\/strong>nderstand gaps in the patient’s knowledge<\/p>\n I<\/span><\/strong>nform and educate<\/p>\n D<\/span><\/strong>irect to additional support<\/p>\n E<\/span><\/strong>mpower the patient<\/p>\n Veerle Lamotte covers steps 1 and 2 of the GUIDE framework and explains why it\u2019s important to G<\/u><\/strong>ain insight into the goals of treatment<\/strong> and care<\/strong> as a first step in supporting your patients along the agreed treatment journey and how to U<\/u><\/strong>nderstand the gaps in the patient\u2019s knowledge<\/strong>, allowing you to prioritise where you focus when it comes to informing and educating the patient.<\/p>\n In the second newsletter, Joanie Pfahl and Jennifer Sutton cover step 3 of the GUIDE Communication Framework and explain the importance of I<\/u>nforming and educating<\/strong> the patient, and why it is essential for nurses to have up-to-date knowledge<\/strong> about the disease and common symptoms, key studies relating to nmCRPC, treatment aims and options, potential side effects and proactive management as addressing patients\u2019 knowledge gaps <\/strong>in the right way is critical in managing their treatment successfully.<\/p>\n In the third newsletter, Jason Alcorn explains how to D<\/span>irect the<\/strong> patient and the carer to<\/strong> additional support<\/strong> and the importance of E<\/span>mpowering the patient<\/strong>, making them feel they can actively participate in the shared decision-making and treatment process<\/strong>, and why these steps are an important part of a successful treatment journey<\/strong>.<\/p>\n","protected":false},"author":{"id":1,"first_name":"Francisco","nickname":"Superadmin","email":"jose.santos@cor2ed.com"},"featured_media":1170,"menu_order":0,"template":"","labels":[4],"keywords":[],"class_list":["post-1173","programmes","type-programmes","status-publish","has-post-thumbnail","hentry","labels-genitourinary-oncology-medical-educational-programmes"],"programme_info_project-code":"","programme_info_type":"","programme_info_sub-type":"","programme_info_medical-affairs":"","programme_info_series":"yes","programme_info_series-uid":"1173","programme_info_series-number":"1","programme_info_multiple-media":"","programme_info_subtitle":" Veerle Lamotte explains why it\u2019s important to gain insight into the goals of treatment and understand gaps in the patient's knowledge.<\/p>","programme_info_supporter-disclaimer":"","programme_info_acknowledgement":"","programme_info_learning-objetives":"","programme_info_pop-up":"","programme_info_pop-up-text":"","programme_info_pop-up-button-1":"","programme_info_pop-up-button-2":"","programme_therapeutic-areas_therapeutic-areas":["621"],"programme_connect_connect":"781","programme_experts_experts":["131"],"programme_partnerships_partnerships":"","programme_accreditations_accreditations":["191663"],"programme_programmes_programmes":"","programme_connects_connects":"","programme_users_users":"","programme_medias_media_collection":"1","programme_medias_media_show_0":"","programme_medias_media_group_0":"","programme_medias_media_project-code_0":"","programme_medias_media_title_0":"","programme_medias_media_subtitle_0":"","programme_medias_media_description_0":"","programme_medias_media_type_0":"vimeo","programme_medias_media_youtube_0":"","programme_medias_media_vimeo_0":"636351934","programme_medias_media_castos_0":"1156458","programme_medias_media_castos-video_0":"","programme_medias_media_spotify_0":"","programme_medias_media_spotify-video_0":"","programme_medias_media_apple_0":"","programme_medias_media_apple-video_0":"","programme_medias_media_google_0":"","programme_medias_media_google-video_0":"","programme_medias_media_url_0":"","programme_medias_media_scorm_0":"","programme_medias_media_file_0":"","programme_medias_media_duration_0":"4","programme_medias_media_overview_0":"","programme_medias_media_audio-transcript_0":" Hello, I\u2019m Veerle Lamotte, an oncology nurse practitioner at Antwerp University Hospital, and I\u2019m here today to talk about strengthening shared decision making between nmCPRC patients and the healthcare team using the GUIDE Communication Framework.<\/p>\r\n Today I want to talk about non-metastatic castrate-resistant prostate cancer and gain insight into the goals of treatment and understand the gaps in patients\u2019 knowledge. nmCPRC is characterised by a progressively increasing PSA level, in the absence of clear, radiological evidence of metastatic disease, despite a castrate level of testosterone.<\/p>\r\n